Medical device tax suspension will rejuvenate U.S. market.
The suspension of the medical device excise tax, which was implemented in 2013 as part of the Patient Protection and Affordable Care Act (PPACA, also known as Obamacare), will have positive consequences for the U.S. medical device market over the next few years, claims an analyst with research and consulting firm GlobalData.
The tax, which imposed a 2.3 percent levy on U.S. sales of medical devices, to be paid by manufacturers or importers, was suspended on Dec. 18, 2015, after the Consolidated Appropriations Act 2016 was signed. The Act induces a two-year moratorium on the tax, effective Jan. 1, 2016 to Dec. 31,2017.
According to Jennifer Ryan, GlobalData's analyst covering Medical Devices, the tax was originally implemented to generate around $30 billion in funds to support the PPACA, under the assumption that greater access to healthcare coverage would create a larger market for medical devices. However, the first half of 2013 saw the tax raising only 60 percent of the expected amount.
Ryan said, "As well as lacking effectiveness, the tax had many costly consequences for manufacturers, and was particularly crippling to smaller companies, which were forced to face challenges such as layoffs, cuts to research and development efforts, and delayed expansion plans."
"The tax also threatened to seize much of the money spent on product innovation and advancement in the U.S. medical device market, which was already struggling under stringent regulatory and reimbursement procedures," she noted.
Ryan added that there were further concerns that patient welfare would be affected by U.S. companies looking to market products through distribution channels overseas in order to avoid strict regulations, thereby preventing U.S. patients from accessing the latest technologies.
GlobalData believes the temporary repeal of the tax will be a relief to small and mid-sized companies, which were struggling under its weight over the past three years. However, this will be short-lived unless further legislative action is taken, since the tax is set to be automatically reinstated on Jan. 1, 2018.
"While there are clear arguments for making the repeal permanent, there are other consequences to take into account, as funds originally garnered from the medical device excise tax, largely used to back the PPACA, will need to be found elsewhere to prevent any negative effects on the U.S. healthcare market," Ryan concluded.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Washington Roundup|
|Publication:||Orthopedic Design & Technology|
|Date:||Jan 1, 2016|
|Previous Article:||FDA narrows "convenience kit" definition for UDI labeling.|
|Next Article:||Foretelling the year in medtech finance.|